Zimmer Biomet Holdings (Zimmer Biomet Holdings) Debt-to-Equity

: 0.47 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Zimmer Biomet Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $900 Mil. Zimmer Biomet Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5,013 Mil. Zimmer Biomet Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $12,481 Mil. Zimmer Biomet Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.47.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Zimmer Biomet Holdings's Debt-to-Equity or its related term are showing as below:

ZBH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.21 Med: 0.66 Max: 1.16
Current: 0.47

During the past 13 years, the highest Debt-to-Equity Ratio of Zimmer Biomet Holdings was 1.16. The lowest was 0.21. And the median was 0.66.

ZBH's Debt-to-Equity is ranked worse than
71.03% of 711 companies
in the Medical Devices & Instruments industry
Industry Median: 0.2 vs ZBH: 0.47

Zimmer Biomet Holdings Debt-to-Equity Historical Data

The historical data trend for Zimmer Biomet Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.66

0.67

0.56

0.49

0.47

Zimmer Biomet Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.49	0.49	0.48	0.45	0.47

Competitive Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zimmer Biomet Holdings Debt-to-Equity Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Debt-to-Equity falls into.

Zimmer Biomet Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Zimmer Biomet Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(900	+	5012.6)	/	12480.5
	=	0.47

Zimmer Biomet Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(900	+	5012.6)	/	12480.5
	=	0.47

Zimmer Biomet Holdings (NYSE:ZBH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Zimmer Biomet Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings (Zimmer Biomet Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ZIM:Germany ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Executives

Syed A. Jafry	director	345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli	director	C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley	director
Robert Hagemann	director	3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson	director	2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard	director	711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Chad F Phipps	officer: Assoc. Gen. Counsel, Corp. Sec	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van	officer: Pres, Europe, M. East & Africa	345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato	officer: VP, Controller & CAO	C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Sang Yi	officer: President, Asia Pacific	345 E. MAIN STREET, WARSAW IN 46580
Lori Winkler	officer: SVP and CHRO	345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson	officer: SVP & CSO	345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson	director, officer: President and CEO	ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau	officer: Group President	345 E. MAIN STREET, WARSAW IN 46580